INTRODUCTION
Significant progress has been made in the identification and characterization of cell membrane receptors in the past decade. Compounds have been synthesized that can be labeled to high specific activity and will still bind to receptors with high affinity (1) . These agents have been used primarily for the in vitro identification and localization of receptors in specific tissues. In the study of the beta adrenergic receptor, antagonists have been preferentially used in that they may demonstrate less nonspecific membrane binding and do not undergo chemical oxidation in the same manner as catecholamines (2) (3) (4) . The synthesis, several years ago, of 3-indoloxy-l-(2-p-hydroxybenzylpropyl-2-amino) isopropanol, called hydroxybenzylpindolol (5) , provided an agent that could readily be labeled with iodine and still maintain its high affinity binding to beta receptors with a reported dissociation rate constant (KD)' of -0.1 nM (6, 7) . In vitro characterization of cell membrane receptors, however, does not provide data concerning receptor occupancy by endogenous agonists in the intact animal and consequently about mechanisms that may be important in the regulation of synaptic activity.
This study was undertaken to define the in vivo distribution of 1251-hydroxybenzylpindolol and to determine whether this could be used to measure beta receptor binding in a particular organ. Specific binding was identified by comparing the distribution data from control animals with that from animals who had previously received the beta blocking agent, propranolol. To further validate that such changes in 125I_ hydroxybenzylpindolol distribution are related to beta receptor binding, several lines of evidence were generated. Agonist pretreatment with epinephrine was shown to inhibit 1251-hydroxybenzylpindolol binding in a manner identical to that for the antagonist, propranolol. Propranolol inhibition of 1251-hydroxybenzylpindolol binding followed a dose-response pattern that duplicated its physiological effects. An apparent KD as determined from simultaneous serum propranolol levels was similar to that obtained from direct membrane binding studies. Alpha blockade had no effect on 1251-hydroxybenzylpindolol binding. Propranolol-inhibitable binding possessed stereospecificity. Furthermore, this approach detected changes in beta receptor occupancy produced by pharmacologic interventions such as chemical sympathectomy. Finally, specific beta receptor binding was externally quantitated in a living animal.
METHODS
Hydroxybenzylpindolol was supplied as a reagent grade chemical from Sandoz Ltd. (Basel, Switzerland). The compound was iodinated using a modification of the chloramine-T method (6) . The labeling efficiency averaged 40%. The iodinated product was purified to a theoretical specific activity of -2,000 Ci/mmol using a paper chromatographic technique previously described (6) . The retardation factor (Rf) (0.50) of the iodinated product by thin-layer chromatography on silica gel plates in diethylamine:toluene (5:6) was similar to the starting material.
Biodistribution studies were performed in type CD-1 mice weighing 30-40 g, obtained from the Charles River Breeding Laboratories, Inc., Wilmington, Mass. In all studies, the amount of '25I-hydroxybenzylpindolol injected was -1 pmol (activity of 1-2 uCi). The propranolol-treated animals received the indicated dose of propranolol intravenously either 10 or 15 min before the administration of 1251-hydroxybenzylpindolol.
An initial study was performed in control and propranololpretreated animals to define the distribution of 1251-hydroxybenzylpindolol over time. Tracer distribution was determined following sacrifice of the animals with an overdose of ether; samples of blood, kidney, heart, liver, spleen, stomach, small bowel, thyroid, pancreas, bone, fat, skeletal muscle, and brain were obtained, weighed, and counted in a gamma counter with a window of 20-60 keV. In addition to the tissue samples, an aliquot of injected dose was counted at the same time and results expressed as percent injected dose per organ. Data is expressed as mean ±its standard duration. Comparison of groups was made using the Student t test.
In other experiments, agonist-inhibitable binding was determined following pretreatment with epinephrine. 50-,ug doses of epinephrine were used because higher doses resulted in a significant mortality rate among the treated animals. To insure that the serum level of the drug was maximal, experiments were performed in which the epinephrine was administered simultaneously with the labeled hydroxybenzylpindolol. The same degree of inhibition (50%) of hydroxybenzylpindolol binding in the lung occurred as when the epinephrine was administered 15 min before hydroxybenzylpindolol injection. Reserpine-pretreated animals received three 15-,ug doses intraperitoneally at 48, 36, and 24 h before the study; 6-OH dopamine was administered intraperitoneally in two doses of 5 mg per animal at 36 and 24 h before the study (8) (9) (10) .
External counting. Imaging and external measurement of '251-hydroxybenzylpindolol in an anesthetized rabbit was accomplished with an Ohio-Nuclear 420/550 gamma camera (OhioNuclear, Inc., Subsid. Technicare Corp., Solon, Ohio) using a low-energy parallel hole collimator. High voltage was maximized and a 50% window was used that included the gamma and x-ray emission of 1251. Data was analyzed on a nuclear medicine data system VP450, Ohio-Nuclear, Inc. Regions of interest in the lungs were outlined with a light pen program.
Curves representing pulmonary '25I-hydroxybenzylpindolol activity vs. time after injection were then generated. Nonspecific binding was determined by measuring lung accumulation of 1251-hydroxybenzylpindolol in control rabbits of identical weight that were pretreated with intravenous propranolol (1.5 mg/kg) 15 min before the injection of the label. The curves in Fig. 6 were computed after subtracting this value for each time point. Radioimmunoassay. Antibodies that recognize propranolol with high affinity were raised in the following manner. The bromohydrin of alprenolol was synthesized according to the method of Hoebeke et al. (11) . This was confirmed by nuclear magnetic resonance which showed loss of the olefin proton signal and by elemental analysis of the product (Galbraith Laboratories, Knoxville, Tenn.). The bromohydrin was then reacted with bovine serum albumin that had previously been modified by reaction with N-acetylhomocysteinethiolactone. This resulted in a product with 2 mol of alprenolol bound per mol of albumin (as later determined by radioimmunoassay ofthe hydrolyzed product). New Zealand White rabbits were immunized with 0.5 mg of this immunogen every 3 wk. Approximately 3-4 mo later, antiseruim was harvested that bound both [3H]alprenolol and [3H]propranolol with an apparent KD of 5 nM similar to that previously reported (11, 12) . The final assay employed 100 ,ul sera, 50 ,ul 4 nM [3H]propranolol (final concentration, 1 nM) and 50 Il of a 1:10 or 1:50 dilution of antiserum.2 Separation of bound from free ligand was performed by a double antibody precipitation technique. In the following manner, it was also shown that these antibodies primarily recognized the propranolamine side chain. Thus 4-OH propranolol (an effective beta blocker), alprenolol, and propranolol were recognized with similar affinities despite their different ring structures (apparent KD 5 nM) whereas naphthoxyacetic acid, which possesses an identical ring structure to propranolol, but lacks the requisite side chain, was not recognized by this antibody class. Catecholamines were recognized as a result of the similarity of their ethanolamine side chain but with a 500-fold lower affinity. A variety of other drugs (aldomnet, digoxin, and tricyclic antidepressants) did not react at concentrations at least 10,000-fold greater or not at all.
Catecholamine determination. Serum epinephrine and norepinephrine were measured by the radioisotopic enzymatic method of DaPrada and Zurcher (13) , using an ethanolaminechloroform-methanol solvent system. In this system, both compounds are 0 [3H]methylated and then separated by thinlayer chromatography providing resolution from each other and from circulating precursors. Some hemolysis of samples occurred because of the inability to obtain adequate volumes from the same mice used in the above protocols. However, these measurements were aimed at simply showing a major reduction in catecholamine concentrations following these protocols. Norepinephrine levels in peripheral blood were in the range of 10 ng/ml with epinephrine concentrations averaging 1-3 ng/ml which, to some extent, represents the stress response that these animals undergo (14) .
RESULTS
The blood disappearance of 1251-hydroxybenzylpindolol was rapid, and at 5 min after administration in the control animals, <6% of the injected dose was present in the entire blood volume of the mouse. Data on the distribution of 1251-hydroxybenzylpindolol are summarized in Fig. 1 would duplicate the effects of the antagonist, propranolol. Therefore, the same protocol was employed with the exception that the beta agonist, epinephrine, was used to define specific binding. As can be seen in Fig. 1 , the same fraction and distribution of receptor specific binding resulted as had been obtained utilizing propranolol.
Inhibition of 1251-hydroxybenzylpindolol binding by propranolol pretreatment was a saturable process and occurred at doses of propranolol at which the physiological effects of the drug are observed (15) . A competitive inhibition curve relating serum propranolol concentrations to hydroxybenzylpindolol binding is shown in Fig. 2 Specific 1251-hydroxybenzylpindolol binding demonstrates stereospecificity as seen in Fig. 4 . Doses of 0.1 mg/kg of L-propranolol inhibit -45-50% of 1251_ hydroxybenzylpendolol binding, whereas the D-isomer blocks only 10% ofthe binding at a dose fivefold greater.
Additional studies were performed in chemically sympathectomized animals to determine whether changes in 1251-hydroxybenzylpindolol binding in vivo might reflect alterations in beta receptor occupancy or number. Fig. 5 depicts the result obtained following such a chemical sympathectomy. In these experiments, groups of mice were treated either with reserpine or 6-OH dopamine. Then the typical protocol outlined previously was followed whereby 1251-hydroxy- 1.0 Lung FIGURE 3 A similar protocol was also employed in these experiments with a phentolamine dose of 3.0 mg/kg and a propranolol dose of 1.5 mg/kg. The mean and its standard deviation is shown (P < 0.001 for propranolol-treated grotups (Pr) vs. control groups (C); P < 0.1 for phentolamine-treated grouips (Ph) vs. control grouips; n = 10).
benzylpindolol binding in saline-treated controls was compared with that in propranolol-treated animals. After the reserpine treatment, the concentrations of 1251-hydroxybenzylpindolol in the lungs rose markedly as shown in Fig. 5 Con-Reser-6 OH trol pine Dopamine FIGURE 5 Mice were pretreated with either reserpine or 6-OH dopamine as described in Methods. The same protocol as described previously was then used. The first graph depicts data from control, reserpine, and 6-OH dopamine-treated animals with and without propranolol pretreatment (1.5 mg/kg). The second graph shows specific binding only for each of these groups. Differences between the propranolol-treated and control animals in each group were significant at the P < 0.001 level (n = 10).
dopamine infusion which produced a chemical sympathectomy via a different mechanism. Both drugs resulted in a significant depletion of norepinephrine levels measured from peripheral blood samples (reserpine 17% of control and 6-OH dopamine 19% ofcontrol). Reserpine also decreased serum epinephrine levels to 24% of control, whereas 6-OH dopamine actually resulted in an increase of 50%. However, epinephrine only accounted for 10-20% of total serum catecholamines. Detection ofbeta receptor binding was also attempted in a living animal and an in vivo competitive inhibition curve was generated. A 3-kg rabbit was anesthetized and injected with 150 ,uCi of 1251-hydroxybenzylpindolol via an ear vein. At 2 min after injection, the lungs were identified from the whole body image utilizing a scintillation camera and total counts were collected for 1 min from a defined area ofinterest within the lung fields. 2 with that following pretreatment with the beta receptor antagonist propranolol. The most significant changes in the distribution of 1251-hydroxybenzylpindolol following such pretreatment occurred in the lung with lesser changes in thyroid, spleen, and blood. These data indicate that the total organ distribution reflects primarily nonspecific binding. We have not yet determined whether specific binding in the lung is primarily in vascular endothelium or parenchymal epithelium. That it does not represent binding to blood elements is based on the simple observation that a much greater degree of specific binding was present in the lung than either in blood or in a densely vascular organ such as spleen. In addition, Bylund et al. (17) have demonstrated in a perfused mouse lung model that the great majority of specifically bound '25I-hydroxybenzylpindolol is associated with tissue elements other than blood. In contrast, the relatively low uptake in the heart and other organs as well as the lack of effect of propranolol pretreatment may be the result of a variety of factors. To some extent this probably reflects the relatively small fraction of the total cardiac output that these organs receive as compared with the lung. The actual dose of 1251_ hydroxybenzylpindolol administered is extremely small (-1 pmol) and thus the relatively high uptake in the lung as compared with the heart and other organs may reflect a bolus effect after intravenous administration. Furthermore, Bylund et al. (17) reported that nonspecific binding in heart tissue was significantly higher (approximately fivefold) than in lung, even when determined during in vitro binding experiments using crude membrane preparations. In particuLlar, the high nonspecific uptake of 125I-hydroxybenzylpindolol in the liver almost certainly reflects the role of this organ in metabolizing drigs of this nature. High first-pass extraction and metabolism of propranolol and other beta blockers by the liver is a well-known phenomenon.
Specific and nonspecific binding was also evaluated by Bylund et al. (17) in mice by comparing the tissue concentration of 125I-hydroxybenzylpindolol 5 min after intravenous injection in control mice with that in mice treated with 1 mg/kg of propranolol. In those studies, specific binding was assessed by removing the tissues and performing in vitro analyses of '251-hydroxybenzylpindolol displacement by propranolol on crude imembrane preparations. Using this approach, specific binding in the brain averaged 66%, whereas in the heart this was 58% and in the lungs 92%. Their results also indicate that as the amount of 1251-hydroxybenzylpindolol injected was increased, specific binding decreased. Furthermore, such a method suffers in that some loss of receptor-bound label will occur as the e(luilibrium is disturbed during the minutes required for the preparation of even a crude membrane fraction.
In an attempt to keep nonspecific binding to a minimum, the amount of 125I-hydroxybenzylpindolol administered to each animal in our studies was held constant at -1 pmol (1-2 ,uCi). We have also observed that by determining specific binding at earlier time points (5-10 min) after injection, one can consistently inhibit 50% of total binding with propranolol pretreatment. Our initial experiments, as demonstrated in Fig. 1 , consistently indicated that 40-50% of total binding was specific when determined at 15 min after '251-hydroxybenzylpindolol administration. Later experiments using an earlier time point demonstrated a higher degree of specific binding in the 50% range (Figs. 2  and 4) . The basis for this finding becomes more obvious after examination of the in vivo binding curves in Fig. 6 . Most of the decrease in total binding over the first 10-20 min appears to represent depletion of the receptor-b)ound ligand pool.
The marked increase in specific binding in the lung after chemical sympathectomy could have been the result of an actual increase in the number of receptors although physiologic data suggest that this may occur over a longer time period (10) . In vitro stuidies have documented this phenomenon of upregulation following either chemical sympathectomy with 6-OH dopamine which produced a decrease in tissue norepinephrine concentrations similar to ours (18), or after chronic receptor blockade (19) . Alternatively, in simply depleting endogenous agonists, a greater fraction of the receptor population may have been available for '251-hydroxybenzylpindolol binding. Recently, a functional parallel for these observations in the lung was reported by Jengo et al. (20) who showed that a greater degree of supersensitivity to exogenous catecholamines occturred in the pulmonary vascular bed than in the systemic bed after chemical sympathectomy. This led them to postulate that the lung has a greater concentration of sympathetic nervous system innervation or of catecholamine receptors than does the systemiiic vasculature.
Zeleznik and Roth (21) have recently detected in vivo binding of 1251-insulin to a high affinity receptor in rabbits. In results analogous to ours, administration of tinlabeled insulin before injection of tracer decreased the distribution space of the labeled insulin, consistent with inhibition of binding resulting from prior saturation of available receptors with the unlabeled hormone. This process was dose dependent and satuirable paralleling our observations with propranololmediated inhibition of '251-hydroxybenzylpindolol binding. Furthermore, by monitoring serum tracer levels they were able to detect apparent reversal of 1251-insulin binding to its receptor during infusion of unlabeled insulin. Our findings utilizing external imaging techniques to quantitate 1251-hydroxybenzylpindolol binding to pulmonary beta receptors are in line with their observations. The decrease in hydroxy- (23, 24) suiffer from the fact that they are (Ijuantitatinig evenits distant from the synapse or are a reflection of only a minor portioni of synaptic activity' (25) .
